Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox in Chronic Migraine: Duration of Benefit and Neuronal Changes
NCT02037425Phase 4Completed
- Start
- Apr 2014
- Primary completion
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in chronic migraine. Primary endpoints: Subject Global Impression of Change at 36 weeks and Duration of onabotulinumtoxinA Over 3 Injection Cycles at 36 weeks. Started Apr 2014; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT02037425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037425.